ArticleScientific reports2016
Transgenic overexpression of VEGF-C induces weight gain and insulin resistance in mice.
Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 49 citations in OpenAlex.
- Association between the triglyceride-glucose index and collateral status in ischemic stroke patients undergoing endovascular therapy.Clinical neuroradiology · 2026Article
- Dysfunctional adipose tissue-lymphatic crosstalk in obesity.Nature reviews. Endocrinology · 2026Review
- Anti-Angiogenic Features of Endostatin in Obesity, Liver Fibrosis, and Hepatocellular Carcinoma.Biomedicines · 2026Review
- Podocyte-directed VEGFC gene therapy prevents increased glomerular permeability and glycocalyx damage in experimental type 1 diabetes.Molecular therapy : the journal of the American Society of Gene Therapy · 2026Article
- An Epigenomic Meta-Analysis of Differentially Methylated Sites in Pre- and Post-Metabolic/Bariatric Surgery Adult Female Patients.Epigenomes · 2025Review
- Multi-parameter tunable synthetic matrix for engineering lymphatic vessels.Communications biology · 2024Article
- VEGFR-3 signaling in macrophages: friend or foe in disease?Frontiers in immunology · 2024Review
- Genome-wide association study and polygenic score assessment of insulin resistance.Frontiers in endocrinology · 2024Article
- Review
- Mapping the transcriptional landscape of human white and brown adipogenesis using single-nuclei RNA-seq.Molecular metabolism · 2023Article
- Article
- Large scale phenotype imputation and in vivo functional validation implicate ADAMTS14 as an adiposity gene.Nature communications · 2023Article
- Increased adipose tissue lymphatic vessel density inhibits thermogenesis through elevated neurotensin levels.Frontiers in cell and developmental biology · 2023Article
- The Role of VEGF Family in Lipid Metabolism.Current pharmaceutical biotechnology · 2023Article
- Lymphatics in Cardiovascular Physiology.Cold Spring Harbor perspectives in medicine · 2022Review
- Lymphangiogenesis and Lymphatic Barrier Dysfunction in Renal Fibrosis.International journal of molecular sciences · 2022Review
- The Role of the VEGF Family in Atherosclerosis Development and Its Potential as Treatment Targets.International journal of molecular sciences · 2022Review
- The role of lacteal integrity and junction transformation in obesity: A promising therapeutic target?Frontiers in endocrinology · 2022Review
- miR-21 mimic blocks obesity in mice: A novel therapeutic option.Molecular therapy. Nucleic acids · 2021Article
- Mesenteric lymphatic dysfunction promotes insulin resistance and represents a potential treatment target in obesity.Nature metabolism · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Obesity comprises great risks for human health, contributing to the development of other diseases such as metabolic syndrome, type 2 diabetes and cardiovascular disease. Previously, obese patients were found to have elevated serum levels of VEGF-C, which correlated with worsening of lipid parameters. We recently identified that neutralization of VEGF-C and -D in the subcutaneous adipose tissue during the development of obesity improves metabolic parameters and insulin sensitivity in mice. To test the hypothesis that VEGF-C plays a role in the promotion of the metabolic disease, we used K14-VEGF-C mice that overexpress human VEGF-C under control of the keratin-14 promoter in the skin and monitored metabolic parameters over time. K14-VEGF-C mice had high levels of VEGF-C in the subcutaneous adipose tissue and gained more weight than wildtype littermates, became insulin resistant and had increased ectopic lipid accumulation at 20 weeks of age on regular mouse chow. The metabolic differences persisted under high-fat diet induced obesity. These results indicate that elevated VEGF-C levels contribute to metabolic deterioration and the development of insulin resistance, and that blockade of VEGF-C in obesity represents a suitable approach to alleviate the development of insulin resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.